Skip to main content
. 2021 Mar 20;10(7):e019274. doi: 10.1161/JAHA.120.019274

Figure 6. Dapagliflozin (DAPA) attenuated mitral regurgitation (MR)‐induced cardiac injury and fibrosis.

Figure 6

Effects of dapagliflozin on (A) survival rate in the Sham, MR, and MR+DAPA groups. B, Representative images of harvested hearts. C, The quantitative analysis of heart weight/body weight, (D) heart weight/tibial length, (E) the wet to dry lung weight ratio, (F) hematoxylin‐eosin staining of heart sections, and (G) Masson trichrome staining of left ventricular tissue in indicated groups; scale bars, 100 µm. H, Quantification of cardiac fibrosis in indicated groups of rat. Data are expressed using mean± SD. Kruskal‐Wallis test and Dunn's post hoc analysis for analysis of group differences. *P<0.05, and* ***P<0.0001 for difference from each group. (N=6–12).